# US 8,278,298 B2 · Inhibition of tau-tau-association

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,298 B2
- Document ID: US8278298B2
- Status: Granted
- Kind: B2
- Application number: 11/636,628
- Filed: 2006-12-11
- Published: 2007-08-16
- Granted: 2012-10-02
- Earliest claimed: 1995-03-27
- Assignees: WisTa Laboratories Ltd.
- Inventors: Claude Michel Wischik; Patricia Carol Edwards; Charles Robert Harrington; Martin Roth; Aaron Klug
- Web page: https://patentgrep.com/patent/US8278298B2

## CPC

- G01N 33/502: {for testing non-proliferative effects}
- A61K 31/54: having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/5058: {Neurological cells}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2333/4709: Amyloid plaque core protein
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2800/28: Neurological disorders
- G01N 2800/2821: Alzheimer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A composition and use thereof for the prophylaxis or treatment of Alzheimer's disease, motor neurone disease, Lewy body disease, Pick's disease or progressive supranuclear palsy. The composition includes an agent which modulates or inhibits tau-tau association and which does not inhibit tau-tubulin binding. In the method the agent is administered to an individual in order to achieve the desired therapeutic effect. Preferably the agent which is administered is a phenothiazine compound.

## Claims

### Claim 1

A method for the prophylaxis of Alzheimer's disease, motor neurone disease, Lewy body disease, Pick's disease, or progressive supranuclear palsy, which method comprises administering to a subject in need thereof an effective amount of an agent which modulates or inhibits tau-tau association and which does not inhibit tau-tubulin binding.

### Claim 2 (depends on 1)

A method according to claim 1 for the prophylaxis of Alzheimer's disease.

### Claim 3 (depends on 1)

A method according to claim 1 wherein said agent is phenothiazines of the formulae:
wherein:
R1, R3, R4, R6, R7, and R9 are independently selected from hydrogen, halogen, hydroxy, carboxy, substituted or unsubstituted alkyl, haloalkyl or alkoxy;
R5, each R10 and each R11 are independently selected from hydrogen, hydroxy, carboxy, substituted or unsubstituted alkyl, haloalkyl or alkoxy; and pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 3)

A method according to claim 3 wherein: R1, R3, R4, R5, R6, R7, R9, each R10 and each R11 are independently selected from hydrogen, —CH3, —C2H5 or —C3H7.

### Claim 5 (depends on 3)

A method according to claim 3 wherein said agent is a phenothiazine of the formula (I):
wherein:
R1, R3, R4, R6, R7, and R9 are independently selected from hydrogen, halogen, hydroxy, carboxy, substituted or unsubstituted alkyl, haloalkyl or alkoxy; R5, R10 and R11 are independently selected from hydrogen, hydroxy, carboxy, substituted or unsubstituted alkyl, haloalkyl or alkoxy; and pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 5)

A method according to claim 5 wherein R5 is hydrogen.

### Claim 7 (depends on 1)

A method according to claim 1, wherein said compound is selected from the group consisting of: Toluidine Blue O, thionine, Azure A, Azure B, and 1,9-dimethyl-Methylene Blue.

### Claim 8

A method for the prophylaxis of Alzheimer's disease, motor neurone disease, Lewy body disease, Pick's disease, or progressive supranuclear palsy, which method comprises administering to a subject in need thereof an effective amount of Methylene Blue.

### Claim 9 (depends on 8)

A method according to claim 8, for the prophylaxis of Alzheimer's disease.
